Study reveals pivotal insights into the progression of Parkinson’s disease

Parkinson’s disease, the second most common type of progressive dementia after Alzheimer’s disease, affects nearly 1 million people in the U.S. and an estimated 10 million individuals worldwide.

CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

September 10, 2024

Generous Blood Transfusions Not Beneficial for Some With Burst Brain Aneurysms

For people with aneurysmal subarachnoid hemorrhage and anemia, there was no significant neurological benefit from getting red blood cell transfusions more liberally, the SAHARA randomized

December 11, 2024

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly

August 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.